| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity J Tsai, JT Lee, W Wang, J Zhang, H Cho, S Mamo, R Bremer, S Gillette, ... Proceedings of the National Academy of Sciences 105 (8), 3041-3046, 2008 | 1602 | 2008 |
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases KSM Smalley, NK Haass, PA Brafford, M Lioni, KT Flaherty, M Herlyn Molecular cancer therapeutics 5 (5), 1136-1144, 2006 | 523 | 2006 |
| Adhesion, migration and communication in melanocytes and melanoma NK Haass, KSM Smalley, L Li, M Herlyn Pigment cell research 18 (3), 150-159, 2005 | 513 | 2005 |
| Normal human melanocyte homeostasis as a paradigm for understanding melanoma NK Haass, M Herlyn Journal of Investigative Dermatology Symposium Proceedings 10 (2), 153-163, 2005 | 282 | 2005 |
| An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells KSM Smalley, R Contractor, NK Haass, AN Kulp, GE Atilla-Gokcumen, ... Cancer research 67 (1), 209-217, 2007 | 277 | 2007 |
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when … NK Haass, K Sproesser, TK Nguyen, R Contractor, CA Medina, ... Clinical Cancer Research 14 (1), 230-239, 2008 | 271 | 2008 |
| Targeting glutamine transport to suppress melanoma cell growth Q Wang, KA Beaumont, NJ Otte, J Font, CG Bailey, M van Geldermalsen, ... International journal of cancer 135 (5), 1060-1071, 2014 | 236 | 2014 |
| The role of altered cell–cell communication in melanoma progression NK Haass, KSM Smalley, M Herlyn Journal of molecular histology 35, 309-318, 2004 | 228 | 2004 |
| A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells JR Stehn, NK Haass, T Bonello, M Desouza, G Kottyan, H Treutlein, ... Cancer research 73 (16), 5169-5182, 2013 | 201 | 2013 |
| PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas JT Lee, L Li, PA Brafford, M Van Den Eijnden, MB Halloran, K Sproesser, ... Pigment cell & melanoma research 23 (6), 820-827, 2010 | 195 | 2010 |
| Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion KSM Smalley, P Brafford, NK Haass, JM Brandner, E Brown, M Herlyn The American journal of pathology 166 (5), 1541-1554, 2005 | 186 | 2005 |
| BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ... Cell death & disease 10 (5), 342, 2019 | 161 | 2019 |
| Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study FJ Moloney, P Guitera, E Coates, NK Haass, K Ho, R Khoury, ... JAMA dermatology 150 (8), 819-827, 2014 | 151 | 2014 |
| Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance F Ahmed, NK Haass Frontiers in oncology 8, 173, 2018 | 147 | 2018 |
| In vitro three-dimensional tumor microenvironment models for anticancer drug discovery KSM Smalley, M Lioni, K Noma, NK Haass, M Herlyn Expert opinion on drug discovery 3 (1), 1-10, 2008 | 142 | 2008 |
| A stress-induced early innate response causes multidrug tolerance in melanoma D Ravindran Menon, S Das, C Krepler, A Vultur, B Rinner, S Schauer, ... Oncogene 34 (34), 4448-4459, 2015 | 135 | 2015 |
| Real‐time cell cycle imaging during melanoma growth, invasion, and drug response NK Haass, KA Beaumont, DS Hill, A Anfosso, P Mrass, MA Munoz, ... Pigment cell & melanoma research 27 (5), 764-776, 2014 | 135 | 2014 |
| Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737 KM Lucas, N Mohana-Kumaran, D Lau, XD Zhang, P Hersey, DC Huang, ... Clinical cancer research 18 (3), 783-795, 2012 | 124 | 2012 |
| Modeling Melanoma In Vitro and In Vivo KA Beaumont, N Mohana-Kumaran, NK Haass Healthcare 2 (1), 27-46, 2013 | 122 | 2013 |
| Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels KSM Smalley, R Contractor, NK Haass, JT Lee, KL Nathanson, ... British journal of cancer 96 (3), 445-449, 2007 | 106 | 2007 |
Helmut SchaiderThe University of Queensland在 uq.edu.au 的电子邮件经过验证
